Cytotoxicity of two novel cisplatin analogues, (CPA)2Pt[DOLYM] and (DACH)Pt[DOLYM], to human cancer cells in vitro

Sang Un Choi, Kwang Hee Kim, Eun Jung Choi, Sung Hee Park, Kwan Mook Kim, Youn Soo Shon, Chong Ock Lee

Research output: Contribution to journalArticlepeer-review


Despite the impressive antitumor activity of cisplatin, two major limitations of the drug, that is severe side effects and drug-resistance of cancer cells, make its use difficult for cancer therapy. These limitations have resulted in a great deal of effort having been expended into structural modifications of cisplatin. In this study, we tested two novel cisplatin analogues, (CPA)2Pt [DOLYM] (COMP-I) and (DACH)Pt[DOLYM] (COMP-II), for the mode of cytotoxic action against human tumor cells comparing with cisplatin and carboplatin in vitro. These two novel analogues had considerable cytotoxic activities against five kinds of human solid tumor cells, and especially COMP-II was more effective on HCT15 colon cancer cells than other compounds. In addition, COMP-II had cytostatic activity at low concentrations (10∼0.3 μg/ml), but other compounds revealed little effect on tumor growth at the low concentration.

Original languageEnglish
Pages (from-to)151-156
Number of pages6
JournalArchives of Pharmacal Research
Issue number2
StatePublished - Apr 1999


  • Cisplatin
  • Cytotoxicity
  • Human cancer cells


Dive into the research topics of 'Cytotoxicity of two novel cisplatin analogues, (CPA)2Pt[DOLYM] and (DACH)Pt[DOLYM], to human cancer cells in vitro'. Together they form a unique fingerprint.

Cite this